SCHEMBL1050558

SCHEMBL1050558

COCCOc1cccc(C(=O)OC)c1OCCOC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
TSHR P16473 3/20 0.47
KDM4E B2RXH2 4/20 0.47
MAPT P10636 3/20 0.46
HSP90AA1 P07900 2/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HPGD P15428 2/20 0.46
GAA P10253 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 2/20 0.44
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1054528 0.92 HPGD (0.55) ALDH1A1TSHRKDM4EMAPTHSP90AA1
SCHEMBL28277529 0.86 ALDH1A1 (0.54) ALDH1A1TSHRKDM4EMAPTHTT
SCHEMBL385973 0.85 HSP90AA1 (0.59) ALDH1A1TSHRKDM4EMAPTHSP90AA1
SCHEMBL1053746 0.85 SLC6A3 (0.63) ALDH1A1TSHRKDM4EMAPTNPSR1
SCHEMBL28821678 0.84 LMNA (0.50) ALDH1A1TSHRKDM4EMAPTHTT
SCHEMBL17090762 0.84 LMNA (0.57) ALDH1A1TSHRKDM4EMAPTHSP90AA1
SCHEMBL28285304 0.83 CHEK1 (0.51) ALDH1A1TSHRKDM4EMAPTHSP90AA1
SCHEMBL28478929 0.81 ALDH1A1 (0.66) ALDH1A1TSHRKDM4EMAPTHSP90AA1
SCHEMBL7977563 0.81 KDM4E (0.56) ALDH1A1TSHRKDM4EMAPTHSP90AA1
SCHEMBL14461315 0.80 RXFP1 (0.50) ALDH1A1TSHRKDM4EMAPTHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872014-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-01-18 US disclosed
EP-1648455-A4 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2009-03-04 EP disclosed
US-20070032515-A1 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2007-02-08 US disclosed
EP-1648455-A2 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-04-26 EP disclosed
WO-2005009389-A2 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032515-A1 Anaplastic lymphoma kinase modulators and methods of use ALK, MALT1, BCL6 ALDH1A1 1285/4885TSHR 3172/4885KDM4E 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.